Although PFI-2 is not licensed for diabetic complications, including DKD, the findings provide a proof of concept to translate these studies and the continued development of novel Set7 inhibitors.51 Taken together, our findings have provided new insights into Set7 regulating EDMT and IGFBP5. This evidence concerns the gene SETD7 and diabetic kidney disease.